Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
Recap by typeshit. Post by @drjonathanstegall on Instagram.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
A woman with four triglyceride-driven pancreatitis episodes came off insulin and had none for 12 months. The authors stress it shows association, not cause.
Coroner David Ryan found Norton had been taking double his prescribed dose and urged Australia's TGA to tighten rules on peptides, limiting them to clinical trials.
An official Gov.il notice flags illegal peptides marketed for weight loss and muscle building as a possible health risk. Details are on the government page.
Loading…